Is ACAD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

3,250 people get ACAD articles and Market Currents by email alert.

Get email alerts on ACAD »

HEADLINES:

ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

Business Wire (Mon, 4:01PM)
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index

Business Wire (Mon, 9:00AM)
2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
Scott Matusow • Wed, May 15 • 11 Comments
ACADIA Pharmaceuticals Prices Public Offering of Common Stock

Business Wire (May 15, 2013)
ACADIA Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013

Business Wire (Apr 30, 2013)
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • Mon, Apr 29 • 15 Comments
Hedge Funds Are Buying These 2 Biotech Stocks
Equity Options Guru • Fri, Apr 26 • 1 Comment
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013

Business Wire (Apr 25, 2013)
Analyzing Market Efficiency: Why Future Catalysts Imply Sanuwave Still Has Room To Double
Logical Assessment • Tue, Apr 23 • 3 Comments
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Trade In Mexico • Thu, Apr 18 • 14 Comments
Thursday's BioPharma Trade Movers
Scott Matusow • Thu, Apr 18 • 30 Comments
2 Biotechs And A Retailer With Recent Intensive Insider Selling
Markus Aarnio • Thu, Apr 18 • 9 Comments
FDA Agrees To Expedited Path To NDA For Pimavanserin
Jason Napodano • Fri, Apr 12 • 5 Comments
Is Acadia A Buy After Jumping Over 50%?
C.R. Jackson • Fri, Apr 12 • 9 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Apr 12 • 2 Comments
This Biopharma Is Ready To Be Shorted
EnhydrisPECorp • Fri, Apr 12 • 17 Comments
ACADIA Pharmaceuticals' CEO Hosts Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA Conference (Transcript)
Thu, Apr 11 • 2 Comments
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA

Business Wire (Apr 11, 2013)

FDA Agrees To Expedited Path To NDA For Pimavanserin
Jason Napodano • Fri, Apr 12 • 5 Comments

FDA Agrees To Expedited Path To NDA For Pimavanserin
Jason Napodano • Fri, Apr 12 • 5 Comments
Is Acadia A Buy After Jumping Over 50%?
C.R. Jackson • Fri, Apr 12 • 9 Comments
This Biopharma Is Ready To Be Shorted
EnhydrisPECorp • Fri, Apr 12 • 17 Comments
Why Acadia Pharmaceuticals Remains A Strong Buy
Carl Cachia • Sat, Apr 6 • 24 Comments
Is There Any Potential Left In ACADIA Pharmaceuticals?
Efsinvestment • Mon, Apr 1 • 4 Comments
Is Acadia An Acquisition Target?
Brian L. Wilson • Tue, Mar 26 • 7 Comments
Acadia Forges Forward With Pimavanserin
PropThink • Wed, Mar 13 • 11 Comments
ACADIA Making A Strong Case For A Long-Term Investment
Trading Maven • Fri, Dec 14, 2012 • 10 Comments
Acadia Financing Relieves Pressure And Sets The Stage For Progress
PropThink • Wed, Dec 12, 2012 • 2 Comments
An Alternative View Of Acadia Pharmaceuticals' Phase III Results
EnhydrisPECorp • Mon, Dec 10, 2012 • 31 Comments
Acadia Pharmaceuticals: Making Big Waves
Efsinvestment • Fri, Dec 7, 2012 • 2 Comments
2 Biotech 'Monster Rallies' That Caught Wall Street's Attention
Brian L. Wilson • Wed, Dec 5, 2012 • 8 Comments
Acadia Hits Home Run In Phase III Trial And Brings Market Focus To Parkinson's
Vineet Dutta • Mon, Dec 3, 2012 • 7 Comments
Is Acadia Pharmaceuticals Almost Tripling On Phase III Data A Good Omen For Celsion?
Heisenberg Principle • Thu, Nov 29, 2012 • 14 Comments
Acadia Hits Home Run With Pimavanserin Data
PropThink • Wed, Nov 28, 2012 • 13 Comments
Acadia Rockets Into The Stratosphere On Clinical Trial Data
Brian L. Wilson • Wed, Nov 28, 2012 • 13 Comments
Acadia Pharmaceuticals And Galena Biopharma: What A Difference A Trial Design Can Make
Brian Nichols • Wed, Nov 28, 2012 • 20 Comments
Acadia Investors Await Clinical Trial Results For Pimavanserin
Brian L. Wilson • Tue, Nov 27, 2012 • 5 Comments
Acadia's Bubbling To Move Higher
James Stocklasar Thomas Jr. • Thu, Oct 18, 2012 • 24 Comments
Why Acadia May Be This Year's Holiday Prize
James Stocklasar Thomas Jr. • Wed, Oct 17, 2012 • 28 Comments

2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
Scott Matusow • Wed, May 15 • 11 Comments
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • Mon, Apr 29 • 15 Comments
Hedge Funds Are Buying These 2 Biotech Stocks
Equity Options Guru • Fri, Apr 26 • 1 Comment
Analyzing Market Efficiency: Why Future Catalysts Imply Sanuwave Still Has Room To Double
Logical Assessment • Tue, Apr 23 • 3 Comments
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013
Trade In Mexico • Thu, Apr 18 • 14 Comments
Thursday's BioPharma Trade Movers
Scott Matusow • Thu, Apr 18 • 30 Comments
2 Biotechs And A Retailer With Recent Intensive Insider Selling
Markus Aarnio • Thu, Apr 18 • 9 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Apr 12 • 2 Comments
The 9 Levels Of Biotechnology And Who Should Invest: Part 2
Brian Nichols • Mon, Apr 8 • 12 Comments
Biotech's Fallen Angels: Identifying Irrational Market Behavior
Logical Assessment • Mon, Apr 8 • 5 Comments
Cramer's Lightning Round - Don't Go Down The Food Chain To Wendy's (4/4/13)
SA Editor Miriam Metzinger • Fri, Apr 5 • 2 Comments
Acadia Pharmaceuticals Implies Sanuwave Could Triple On New Study Design
Nouvelle Asset Management • Fri, Apr 5 • 4 Comments
Biotech: Hedging While Speculating
Nathaniel Munson • Fri, Mar 29 • 36 Comments
3 Small Cap Biopharmas Primed To Move Much Higher Now
Scott Matusow • Wed, Mar 27 • 12 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Tue, Mar 26
Last Week's Biotech Movers: Are Any A Buy?
Brian Nichols • Mon, Mar 25 • 16 Comments
Cramer's Lightning Round - I Didn't Get To The Promised Land With Energy Transfer Partners (3/22/13)
SA Editor Miriam Metzinger • Sun, Mar 24
The Blitz: Are These Stocks Presenting Upside?
Brian Nichols • Sun, Mar 24 • 19 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Mar 22 • 1 Comment
2 Biopharma Stocks Rallying On Fresh Clinical Trial Data
Brian L. Wilson • Thu, Mar 21 • 1 Comment

ACADIA Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
ACADIA Pharmaceuticals' CEO Hosts Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA Conference (Transcript)
Thu, Apr 11 • 2 Comments
ACADIA Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
ACADIA Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 5, 2012 • 2 Comments
ACADIA Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Aug 10, 2012
ACADIA Pharmaceuticals, Inc. Q3 2009 Earnings Conference Call
Mon, Nov 9, 2009
Acadia Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Mon, Mar 9, 2009
ACADIA Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Wed, Nov 5, 2008
ACADIA Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Mon, May 5, 2008
ACADIA Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Tue, Mar 11, 2008
ACADIA Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Wed, Mar 5, 2008
Acadia Pharmaceuticals Q3 2007 Earnings Call Transcript
Mon, Nov 5, 2007

ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

Business Wire (Mon, 4:01PM)
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index

Business Wire (Mon, 9:00AM)
ACADIA Pharmaceuticals Prices Public Offering of Common Stock

Business Wire (May 15, 2013)
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013

Business Wire (Apr 30, 2013)
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013

Business Wire (Apr 25, 2013)
The Technical Indicator: Charting the S&P’s uptrend, and its next hurdle

at MarketWatch.com (Apr 23, 2013)
Early Movers: JCP, BBBY, YUM & More

at CNBC.com (Apr 11, 2013)
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA

Business Wire (Apr 11, 2013)
The Technical Indicator: S&P 500 chips away at all-time highs

at MarketWatch.com (Apr 9, 2013)
Lightning Round: SandRidge Energy, Wendy's & More

at CNBC.com (Apr 4, 2013)
Lightning Round: Blackstone Group, Sprint & More

at CNBC.com (Mar 22, 2013)
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting

Business Wire (Mar 20, 2013)
After-Hours Buzz: EA, BAC, DFS & More

at CNBC.com (Mar 18, 2013)
ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013

Business Wire (Mar 13, 2013)
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012

Business Wire (Mar 12, 2013)
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013

Business Wire (Mar 5, 2013)
ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013

Business Wire (Feb 25, 2013)
ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013

Business Wire (Feb 5, 2013)
Lightning Round: Restoration Hardware, Citigroup & More

at CNBC.com (Jan 22, 2013)

ACAD vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. We currently are developing a portfolio consisting of four product candidates including our most advanced compound, pimavanserin,... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 4:14 PM Acadia Pharmaceuticals (ACAD) announces a public offering. Size and terms of the offering weren't disclosed. Jefferies and Cowen are acting as the joint book-running managers for the offering. Shares -5% AH. Comment! [Healthcare, On the Move]
Tuesday, May 7, 8:05 PM ACADIA (ACAD): Q1 EPS of -$0.08 in-line. Revenue of $417K misses by $33K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 22, 11:17 AM Acadia Pharmaceuticals (ACAD +8.1%) spikes higher this morning, breaking out of a technical range on no specific news. The stock has been considerably volatile over the past month, having risen over 700% since November of last year on the back of strong results from its Parkinson's drug Pimavanserin. Comment! [Healthcare, On the Move]
Sunday, April 14, 8:25 AM The reconstitution of the Russell indexes coming up in June, Credit Suisse aims to anticipate who's in and who's out. The rules-based approach of the Russell 2000 has allowed arbitragers to profit each summer by front-running the moves, making the Russell 2000 ETF (IWM) a poorer play for small cap fans than IJR . Expected among the top 25 adds are ARCP, SRPT, PBYI, ACAD, and WSTC. Among the top 25 deletes: CPST, FCEL, CHKE, OMER, and EML. Comment! [Quick Ideas]
Thursday, April 11, 12:49 PM Midday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%. Comment! [On the Move]
Thursday, April 11, 9:10 AM Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move]
Thursday, April 11, 8:05 AM Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR) 4 Comments [Healthcare, On the Move]
Monday, March 25, 12:17 PM Acadia Pharmaceuticals (ACAD +10.1%) gets a big bump on a notable mention from Jim Cramer last Friday CNBC's on Mad Money. "This is the real deal," He says. "There was some profit taking this week, but you should hold onto it. ACAD is a fantastic spec." Additionally, Seeking Alpha contributor Brian Nichols added his two cents as well, calling the stock the safest bet in the biotech space right now after Pimavanserin's encouraging Phase 3 trial results. 1 Comment [Healthcare, On the Move]
Thursday, March 21, 3:43 PM Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing. 1 Comment [Healthcare, On the Move]
Thursday, March 21, 12:57 PM Midday top 10 gainers: ACAD +29%. CMT +19%. EGLE +17%. ANAC +17%. DRAM +18%. HNR +14%. ECT +14%. AFFY +13%. NICK +13%. GNK +12%.
Midday top 10 losers: GMO -18%. BLDP -18%. AMBT -15%. SCHL -15%. CIMT -13%. AQ -13%. CHRM -12%. VTNR -11%. PSUN -10%. CSUN -9%. Comment! [On the Move]
Thursday, March 21, 9:10 AM Premarket gainers: ITMN +12%. CBLI +9%. ACAD +7%. AFFY +6%.
Losers: CIMT -12%. SCHL -11%. BLDP -9%. ORCL -8%. GES -7%. Comment! [On the Move]
Thursday, March 21, 8:31 AM Acadia (ACAD) +6.4% after saying that its Pimavanserin performed well in a Phase III trial, showing a "robust and consistent efficacy...across a wide array of study measures" and confirming previous "positive top-line results." Twice as many patients treated with pimavanserin were rated as "very much improved or much improved" vs those given a placebo. (PR) Comment! [Healthcare, On the Move]
Tuesday, March 19, 10:17 AM Acadia Pharmaceuticals (ACAD +1.7%) gets a lift this morning after Jefferies initiates coverage with a Buy and a $13 price target. The firm says that its lead drug in development, pimavanserin, is a treament for Parkinson's disease psychosis for which there is currently no FDA-approved counterpart. ACAD recently reported positive Phase 3 data, and Jefferies sees the drug as a highly attractive licensing/acquisition target for pharma companies. Comment! [Healthcare, On the Move]
Tuesday, March 19, 9:10 AM Premarket gainers: NPSP +10%. SKUL +7%. ABC +6%. ACAD +5%.
Losers: AFFY -59%. HNR -46%. MTSL -30%. STSI -11%. CAH -8%. DSW -7%. HPT -6%. Comment! [On the Move]
Tuesday, March 12, 4:29 PM ACADIA (ACAD): Q4 EPS of -$0.11 misses by $0.02. Revenue of $380K misses by $90K. Shares -0.5% AH. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, January 28, 12:45 PM Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%. Comment! [On the Move]

StockConsultant
$ACAD confirmed breakout above 14.06, charts analysis http://bit.ly/10gnRwN
Mon, 10:15 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for May 15 2013 | $ACAD $ALXA $CETV $CSIQ $SCTY $SODA $SPU | SharePlanner http://bit.ly/13xbTQb
May 15, 9:20 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

TipRanks
Before ER today: Jefferies Thomas Wei rec Buy $ACAD-med +accelration. Wei ranks 141 of 1929 analysts on tipranks.
May 7, 8:06 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Potential Downgrades (4/30/13): $ACAD, $CBD, $CNH, $HMC, $HNT, $KEX, $LGCY, $MAS, $SSI, $THOR, $THS, $TUP
May 1, 10:24 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
ACADIA Pharmaceuticals ($ACAD) has gained 800% over the last 52-weeks. Steps look like institutional buying. http://yhoo.it/ZjLk0B;c=
Apr 22, 10:52 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jason F
$ACAD Monthly Chart http://bit.ly/120j1nk Its running into resistance but will it matter?
Apr 11, 2:36 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

lazertron
In $ACAD and $STEM. A nice start in the trading day. Also $SNWV received a patent on blood sterlisation using their Shock Wave technology.
Apr 11, 9:32 AM
Reply (5)

• !Report Abuse
View all 5 replies
lazertron: my car ;) Porsche GT3 RS
Apr 11, 10:51 AM
• !Report Abuse
wheelz23: holy ACAD!!!!!
Apr 11, 2:49 PM
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
congrats to $ACAD on not having to do second ph3 study - great news today
Apr 11, 8:30 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Perkins Cove
$ACAD, good trade for those that could trade @7:00am in pre mkt.... http://seekingalpha.com/n/k39t
Apr 11, 8:08 AM
Reply (2)

• !Report Abuse
View all 2 replies
Perkins Cove: I saw a low of 10.75, and a high of 12.50. My broker doesn't start until 8:00am, so no position. Be careful who you pick for a broker.
Apr 11, 8:12 AM
• !Report Abuse
Perkins Cove: I understand Scottrade and Fidelity start @ 7:00. Any others...?
Apr 11, 8:14 AM
• !Report Abuse
Add a reply...

140 characters

StockConsultant
$ACAD continuation breakout watch above 8.57 target 10.16 for a 22.3% gain, stock charts and analysis http://goo.gl/Szq62
Mar 26, 8:53 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

lazertron
In $ACAD and $STEM. A nice start in the trading day. Also $SNWV received a patent on blood sterlisation using their Shock Wave technology.
Apr 11, 9:32 AM
Reply (5)

• !Report Abuse
View all 5 replies
lazertron: my car ;) Porsche GT3 RS
Apr 11, 10:51 AM
• !Report Abuse
wheelz23: holy ACAD!!!!!
Apr 11, 2:49 PM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Now question is is it worth gambling on ($ACAD)?
11/28/12
Reply (1)

• !Report Abuse
View all 1 replies
mitrado: Not unless you like to get crushed by Adam F & the rest of market manipulators. Watch how they will start attacking $ACAD on a daily basis.
Apr 11, 2:32 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$ACAD, good trade for those that could trade @7:00am in pre mkt.... http://seekingalpha.com/n/k39t
Apr 11, 8:08 AM
Reply (2)

• !Report Abuse
View all 2 replies
Perkins Cove: I saw a low of 10.75, and a high of 12.50. My broker doesn't start until 8:00am, so no position. Be careful who you pick for a broker.
Apr 11, 8:12 AM
• !Report Abuse
Perkins Cove: I understand Scottrade and Fidelity start @ 7:00. Any others...?
Apr 11, 8:14 AM
• !Report Abuse
Add a reply...

140 characters

Brian Nichols
After data $ACAD will have $700 million market cap by end of week. It was significantly undervalued
11/27/12
Reply (7)

• !Report Abuse
View all 7 replies
deepankr: What would be a buying point for you after today Brian?
11/27/12
• !Report Abuse
Brian Nichols: I actually bought @ $5.20, but it's only for a trade. I will probably sell tomorrow and then look 4 a better opportunity n the next 2 months
11/27/12
• !Report Abuse
Add a reply...

140 characters

millspap
ACAD biotech runup trade through late october
9/27/12
Reply (3)

• !Report Abuse
View all 3 replies
millspap: What's your opinion on ACAD?
9/27/12
• !Report Abuse
iadops40: Pimavanserin phase III data is due in Nov. a few other trials in early stage. Looks like 3-5 range.
9/27/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I cant buy ACAD now because ATRS is my claim. No way I will sell a single share of it. I just know it will be acquired in the next year.
3/11/12
Reply (10)

• !Report Abuse
View all 10 replies
Scott Matusow: I'd have to study that one TD,, as of now, I dont know anything about it.
3/12/12
• !Report Abuse
TDPeterson123: Was just curious - appreciate your consideration. I'm not selling any ATRS. No. Do you advise keeping a "limit" in place, & how long?
3/12/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I am looking at Acadia Pharma (ACAD) for this week. like what I see with it. Risky pick as a developmental bio, but has large upside to it.
3/11/12
Reply (1)

• !Report Abuse
View all 1 replies
mojojojo1: ATRS seems safer ,digging in
3/11/12
• !Report Abuse
Add a reply...

140 characters

ACAD ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.